Vigya test infogram

A Data-Led Deep Dive Into The World’s Biggest Therapeutic Area

  
Generate a summary of this article
Listen to this article
Beta

add a desc test

This examination of global market trends and the overall structure of the oncology sector sets the stage. Oncology is the pharmaceutical industry’s largest therapeutic area, representing about 18% of global prescription and over-the-counter sales in 2024. At roughly $220bn, the market is forecast to almost double by 2032, growing at 5-9% annually, according to Evaluate consensus forecasts (see Exhibit 1).

Oncology drugs not only account for a large amount of sales but also attract vast R&D investment. Over the last...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

SpotifyApple PodcastsWebsite

More from In Vivo

Vigya test infogram

add a desc test

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 
• By Edwin Elmhirst and Lucie Ellis-Taitt

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

More from Executive Interviews

'Not Going With The Crowd’: Mapping Gene Potential With ProFound Therapeutics

 
• By Anabel Costa-Ferreira

John Lepore, CEO of ProFound Therapeutics and CEO-partner at Flagship Pioneering, discusses the vast possibilities for the human atlas, the benefits of strategic partnering and knowing when to walk away from a project.  

Parexel Execs On Obesity, AI And Data Trends

 
• By Vibha Ravi

Parexel’s chief strategy officer Kushal Gohil, clinical EVP Stephen Pyke and India head Sanjay Vyas share thoughts on possible hurdles to, and the cascading impact of obesity treatments, GenAI progress and the opportunities and challenges of real-world data in India.    

Exeliom’s Bacteria-Focused Approach To Immunotherapy

 
• By Janelle Hart

In Vivo sat down with Benjamin Hadida, CEO of Exeliom, at the 2024 BIO International Convention to discuss how the company is using its first-in-class drug candidate to improve therapeutic responsiveness in immuno-oncology, immuno-inflammation and rare disease.